BIST10014.251,29▼ 0.00%Bitcoin Slides 1.5% Amid Micron Collapse and Market TurbulenceUSD/TRY47.3806▲ 0.20%Micron Commits $250 Billion US Investment, Redefining Chip LandscapeEUR/TRY54.0476▲ 0.30%Morgan Stanley Reaffirms Nvidia as Its Top Semiconductor PickBTC/USD$64,021.99▼ -1.37%Equity Bancshares Q2 2026 Earnings: Net Interest Margin and Efficiency SurgeGOLD6.049,55▲ 0.15%Apple Receives Rare 'Underweight' Rating: Implications for AAPL StockBRENT$84.93▼ 0.00%Bitcoin Pauses, XRP Lags: Market Dynamics and Strategic Takeaways Wall Street's Digital Fortress: Morgan Stanley Opens Crypto Gates via E*TradeBIST10014.251,29▼ 0.00%Bitcoin Slides 1.5% Amid Micron Collapse and Market TurbulenceUSD/TRY47.3806▲ 0.20%Micron Commits $250 Billion US Investment, Redefining Chip LandscapeEUR/TRY54.0476▲ 0.30%Morgan Stanley Reaffirms Nvidia as Its Top Semiconductor PickBTC/USD$64,021.99▼ -1.37%Equity Bancshares Q2 2026 Earnings: Net Interest Margin and Efficiency SurgeGOLD6.049,55▲ 0.15%Apple Receives Rare 'Underweight' Rating: Implications for AAPL StockBRENT$84.93▼ 0.00%Bitcoin Pauses, XRP Lags: Market Dynamics and Strategic Takeaways Wall Street's Digital Fortress: Morgan Stanley Opens Crypto Gates via E*Trade

Global MarketsJuly 16, 2026 at 01:50 PM

Erasca (ERAS) Surges 8.9% on Promising Cancer Trial Results

724FinanceGökberk Uçar

Erasca (ERAS) Surges 8.9% on Promising Cancer Trial Results

Erasca (ERAS) stock surged 8.94% to close at $19.50, driven by promising clinical trial results for its cancer treatment candidate. ERAS-0015 showed a 57% tumor reduction in seven pancreatic cancer patients after eight weeks.

■Jefferies raised its price target by 14% to $24, highlighting undervaluation.

■Hedge funds increased to 51 from 32 in Q1, signaling institutional confidence.

■The company plans a lung cancer trial for ERAS-0015 in H1 2027.

The results position Erasca as a key player in cancer therapy. Additional data on ERAS-0015's combination with panitumumab is expected in H1 2027. Investors are valuing the drug's efficacy and safety profile against competitors like daraxonrasib.